Literature DB >> 7241651

Complementation of adenovirus type 5 host range mutants by adenovirus type 12 in coinfected HeLa and BHK-21 cells.

D T Rowe, F L Graham.   

Abstract

We have studied the ability of adenovirus type 12 (Ad12) to complement the Ad5 transformation-defective host rang (hr) mutants during infection of human cells (HeLa) or hamster cells (BHK-21). The group I mutant hr3 (mapped within 1.3 to 3.7 map units), which is incapable of synthesizing viral DNA, was complemented for both DNA synthesis and infectious virus production in nonpermissive HeLa cells during coinfection with Ad12. Similarly, the group II mutant hr6 (6.1 to 9.4 map units), which does synthesize DNA, was also shown to be complemented for virus production. When the host cells were BHK-21, an established hamster cell line that is permissive for Ad5 but nonpermissive for Ad12 DNA synthesis and virus production, coinfection with Ad5 and Ad12 did not overcome the block to Ad12 DNA synthesis. Coinfection of BHK-21 cells with Ad12 and either hr3 or hr6 leads to the complementation of only the group I mutant (hr3). The inability of Ad12 to complement hr6 in BHK-21 cells may be due to the failure of Ad12 to express an early gene product from the region corresponding to early region 1B (4.5 to 11 map units) Ad5 where hr6 and the other group II mutations are located.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7241651      PMCID: PMC171139     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  BIOCHEMICAL STUDIES ON ADENOVIRUS MULTIPLICATION, VI. PROPERTIES OF HIGHLY PURIFIED TUMORIGENIC HUMAN ADENOVIRUSES AND THEIR DNA.

Authors:  M GREEN; M PINA
Journal:  Proc Natl Acad Sci U S A       Date:  1964-06       Impact factor: 11.205

2.  Complementation of human adenovirus type 5 ts mutants by human adenovirus type 12.

Authors:  J Williams; H Young; P Austin
Journal:  J Virol       Date:  1975-03       Impact factor: 5.103

3.  The response of BHK21 cells to infection with type 12 adenovirus. VI. Synthesis of virus-specific RNA.

Authors:  K Raska; W A Strohl
Journal:  Virology       Date:  1972-03       Impact factor: 3.616

4.  Viral DNA in transformed cells. II. A study of the sequences of adenovirus 2 DNA IN NINE LINES OF TRANSFORMED RAT CELLS USING SPECIFIC FRAGMENTS OF THE VIRAL GENOME;.

Authors:  P H Gallimore
Journal:  J Mol Biol       Date:  1974-10-15       Impact factor: 5.469

5.  Size and location of the transforming region in human adenovirus type 5 DNA.

Authors:  F L Graham; A J van der Eb; H L Heijneker
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

6.  The response of BHK21 cells to infection with type 12 adenovirus. 3. Transformation and restricted replication of superinfecting type 2 adenovirus.

Authors:  W A Strohl; H Rouse; K Teets; R W Schlesinger
Journal:  Arch Gesamte Virusforsch       Date:  1970

7.  Transcription and replication of viral deoxyribonucleic acid in cells coinfected with adenovirus types 2 and 12.

Authors:  S Mak
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

8.  Nonproductive infection of baby hamster kidney cells (BHK21) with adenovirus type 12.

Authors:  W Doerfler
Journal:  Virology       Date:  1969-08       Impact factor: 3.616

9.  Biochemical studies on adenovirus multiplication. IX. Chemical and base composition analysis of 28 human adenoviruses.

Authors:  M Piña; M Green
Journal:  Proc Natl Acad Sci U S A       Date:  1965-08       Impact factor: 11.205

10.  Integration of the deoxyribonucleic acid of adenovirus type 12 into the deoxyribonucleic acid of baby hamster kidney cells.

Authors:  W Doerfler
Journal:  J Virol       Date:  1970-11       Impact factor: 5.103

View more
  12 in total

Review 1.  Expression and interactions of human adenovirus oncoproteins.

Authors:  P A Boulanger; G E Blair
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

2.  Helper function of adenovirus 2 for adenovirus 41 antigen synthesis in semi-permissive and non-permissive cells.

Authors:  C T Tiemessen; A H Kidd
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Adenovirus early region 4 34-kilodalton protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells.

Authors:  F D Goodrum; T Shenk; D A Ornelles
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

4.  Oncogenicity by adenovirus is not determined by the transforming region only.

Authors:  R Bernards; M G de Leeuw; M J Vaessen; A Houweling; A J van der Eb
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

5.  Mapping of an adenovirus function involved in the inhibition of DNA degradation.

Authors:  R B Lai Fatt; S Mak
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

6.  Dependence of tumor-forming capacities of cells transformed by recombinants between adenovirus types 5 and 12 on expression of early region 1.

Authors:  K Shiroki; K Maruyama; I Saito; Y Fukui; K Yazaki; H Shimojo
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

7.  Recombinant human adenoviruses containing hybrid adenovirus type 5 (Ad5)/Ad12 E1A genes: characterization of hybrid E1A proteins and analysis of transforming activity and host range.

Authors:  T Jelinek; F L Graham
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Isolation of a nondefective recombinant between adenovirus type 5 and early region 1A of adenovirus type 12.

Authors:  K Shiroki; I Saito; K Maruyama; H Shimojo
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

9.  Adenovirus E1A gene induction of susceptibility to lysis by natural killer cells and activated macrophages in infected rodent cells.

Authors:  J L Cook; D L May; A M Lewis; T A Walker
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

10.  Expression of adenovirus type 12 early region 1 in KB cells transformed by recombinants containing the gene.

Authors:  K Shiroki; I Saito; K Maruyama; Y Fukui; Y Imatani; K I Oda; H Shimojo
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.